Optiver Holding’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-8,756
Closed -$12.2K 2760
2026
Q1
$12.2K Sell
8,756
-7,057
-45% -$9.7K ﹤0.01% 1183
2025
Q4
$25.5K Buy
15,813
+13,629
+624% +$28.5K ﹤0.01% 990
2025
Q3
$5.96K Buy
+2,184
New +$7.26K ﹤0.01% 1600

Other funds holding AKBA

Optiver Holding's AKBA Position: Q2 2026 in Review

Optiver Holding sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 8,756 shares — an estimated $12.2K sold.

Optiver Holding first reported a position in AKBA in Q3 2025 and held it in 3 quarters. The position peaked at $25.5K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Optiver Holding reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 8,756 Akebia Therapeutics shares in Q2 2026, an estimated $12.2K.
  • Optiver Holding first reported a position in Akebia Therapeutics in Q3 2025 and held it in 3 quarters.
  • Optiver Holding's Akebia Therapeutics position peaked at $25.5K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.